Controversies in primary CNS lymphoma

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 459-464

  Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Immunotherapy; Methotrexate; Molecular genetics; Primary CNS lymphoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHOLESTEROL OXIDASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOSULFATE; THIOTEPA; VINCRISTINE;

BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CHEMOSENSITIVITY; CLINICAL TRIAL; DEMENTIA; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG PENETRATION; EYE TUMOR; GAIT DISORDER; HUMAN; MOLECULAR GENETICS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PATIENT CARE; PROGNOSIS; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; URINE INCONTINENCE;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; METHOTREXATE;

EID: 22544486851     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.459     Document Type: Review

References (34)

1. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18, 3144-3150 (2000).
2. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J. Clin. Oncol. 20, 4643-4648 (2002).
3. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18, 519-526 (2000).
4. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21, 1044-1049 (2003).
5. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter Phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol. 21, 2726-2731 (2003).
6. Abrey LE, Yahalom J, DeAngelis LM. Long-term survival in primary central nervous system lymphoma (PCNSL). J. Clin. Oncol. 16, 859-863 (1998).
7. Sandor V, Stark-Vanes V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 16, 3000-3006 (1998).
8. Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21, 4489-4495 (2003).
9. Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol. 51, 247-252 (2002).
10. Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21, 4151-4156 (2003).
11. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10, 635-643 (1992).
12. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol. 21, 4483-4488 (2003).
13. Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr. Hematol. Oncol. 5, 115-124 (1988).
14. Vassal G, Valteau D, Bonnay M, Patte C, Aubier F, Lemerle J. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin's lymphoma. Pediatr. Hematol. Oncol. 7, 71-77 (1990).
15. Tetef ML, Margolin KA, Doroshow JH et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother. Pharmacol. 46, 19-26 (2000).
16. Omuro AMP, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64, 69-74 (2005).
17. Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58, 1513-1520 (2002). Large retrospective series of primary CNS lymphoma.
18. Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J. International Collaborative Group against primary CNS lymphomas. J. Clin. Oncol. 21, 1649-1650 (2003).
19. Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol. 20, 231-236 (2002).
20. Shibamoto Y, Hayabuchi N, Hiratsuka J et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97, 128-133 (2003).
21. McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46, 51-60 (2000).
22. O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med. Oncol. 16, 211-215 (1999).
23. Pels H, Schulz H, Manzke O, Horn E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neurooncol. 59, 213-216 (2002).
24. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89, 753-754 (2004).
25. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary central nervous system lymphoma with a combination of rituximab and Temozolomide. Neurology 5, 901-903 (2004).
26. Nakamura M, Shimada K, Ishida E, Konishi N. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol. Histopathol. 19, 211-219 (2004).
27. Harada K, Nishizaki T, Kubota H, Harada K, Suzuki M, Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet. Cytogenet. 125, 147-150 (2001).
28. Tilly H, Rossi A, Stamatoullas A et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84, 1043-1049 (1994).
29. Nakamura M, Kishi M, Sakaki T et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 63, 737-741 (2003).
30. Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin. Cancer Res. 9, 1063-1069 (2003).
31. Rubenstein J, Shen A, Fridlyand J et al. Gene expression profile analysis of primary CNS lymphoma: class distinction and outcome prediction. Proc. Am. Assoc. Cancer Res. (2004).
32. Abrey LE, Batchelor TT, Andres JM et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary central nervous system lymphoma. J. Clin. Oncol. (2005) (In Press). International consensus on the appropriate evaluation of primary CNS lymphoma.
33. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23, 9-17 (1992).
34. Abrey LE, Yahalom J, DeAngelis LM. Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48, 18 (1997).